All News
Completely new one for me, Dr Taniguchi presenting on using ear ultrasound to diagnose and monitor disease activity in relapsing polychondritis. Appears useful, I suspect in clinical practice more so for diagnosis. Abstr#0169 #ACR21 @RheumNow https://t.co/PLJtkYkP3A
Richard Conway RichardPAConway ( View Tweet)
Dr Patel @jeffsparks @zach_wallace_md comparative cohort study on CD-20 inhibitors and COVID. ⬆️ mortality, aHR 2.16 . Abstr#0085 #ACR21 @RheumNow https://t.co/wyfEBWurRi
Richard Conway RichardPAConway ( View Tweet)
Dr McDermott @jeffsparks on risk factors for RA-bronchiectasis. Seropositivity, older age at RA onset, and lower BMI⬆️risk. Abstr#0288 #ACR21 @RheumNow https://t.co/7d2ZVWLzn6
Richard Conway RichardPAConway ( View Tweet)
Dr O'Brien on co-existent AAV and RA. Not something I'm used to seeing, but maybe we need to think about it more? 25 cases with RA+AAV, 52 with RA + ANCA but no AAV, not sure what the denominator is here though. Abstr#0428 #ACR21 @RheumNow @profgayecunnane https://t.co/fN3BRpc7UJ
Richard Conway RichardPAConway ( View Tweet)
Dr Adachi presents ⬆️BMD gain with denosumab than risedronate in RA. Non-significant reduction in fractures (very small numbers) Interesting, but need to see fracture benefit in larger study to justify dmab as first line Abstr#0445 #ACR21 @RheumNow https://t.co/GgaS9JZGzb
Richard Conway RichardPAConway ( View Tweet)
Dr Oster presenting on IL-23 inhibitor Risankizumab in PsA. No surprises here, it works. We need comparative efficacy trials! Abstr#0453 #ACR21 @RheumNow https://t.co/mj8TeCqEcg
Richard Conway RichardPAConway ( View Tweet)
Diabetes puts you at risk of cardiovascular disease, right?
What about RA?
Look at this graph and compare the pair.
"already it was impossible to say which was which” - George Orwell, Animal Farm
#ACR21 ABST0287 @RheumNow https://t.co/r0yaeC530l https://t.co/mKJhoyJ2Cn
David Liew drdavidliew ( View Tweet)
Year 2 f/u on PsA, axSpA, or RA using CT-P13, an infliximab (IFX) biosimilar. Pts either naive to IFX or switched from IFX:
💠IFX-naive: improved disease activity
💠IFX-switched: maintained stable disease
💠No new safety concerns
https://t.co/VGBicnq15w
#ACR21 Abst#0817 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Small but important study of LN Class III, IV, and/or V with 6/18 pts considered complete responders by UProt (<500mg/g) continued to⬇️in renal fxn over 5 yrs. Bottom line: even dramatic ⬇️UProt does not tell the whole story.
https://t.co/51x4DlXkJC
#ACR21 Abst#1284 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Infxn risk of 1st year on rituximab for mod to severe SLE vs standard-of-care
🔹Most common SoC Rx: MMF, Aza, and/or cyclophosphamide
🔹🚫significant diff
🔹RTX pts = ⬆️dz duration, ⬆️# of prior meds, ⬇️maintenance steroid dose
https://t.co/AYQFXqlubl
#ACR21 Abst1288 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
SLE: Belimumab + standard rx significantly⬇️risk of severe flares vs placebo.
Greatest in those with:
🔹+dsDNA
🔹low C3 or C4
🔹SLICC/ACR Damage index of 0 (argument for early treatment!)
https://t.co/UcGXEklqwJ
#ACR21 Abst#1295
@RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Dr. Eric Ruderman gives his perspective on PsA data presented during the plenary session on Saturday at the #ACR21 annual meeting.
https://t.co/r9FgBO6VT7 https://t.co/JbV519XQoG
Links:
Dr. John Cush RheumNow ( View Tweet)
Important differences between vascular pathologies seen in #COVID19 and DIC by Dr. D McGonagle
👉Fibrinogen - normal/sl. ⬆ in PIC-assoc'd COVID19 vs. ⬇ in DIC sec to MAS
@RheumNow #ACR21 #MedTwitter
📌https://t.co/DdmAhVIR51 https://t.co/Xw8LKaKcFd
Links:
sheila RHEUMarampa ( View Tweet)
Dr. D.McGonagle on the patterns of dse ➡true #vasculitis vs. vasculitis mimics seen in skin of #COVID19 pts in this very informative slide
🔴Mild/no lung dse: vasc cuffing,⬆type1 IFN
🔴Severe dse: vasc occlusion,⬇type1 IFN
@RheumNow #ACR21 #MedTwitter
https://t.co/Y5S2k7LO1p https://t.co/puBJm4Kd8H
Links:
sheila RHEUMarampa ( View Tweet)
Interesting twist to an #ACR21 keynote lecture: Q&A!👏👏@DoctorYasmin
She even eloquently explained the etymology of crisis-the point in a pt's illness where they might rapidly deteriorate or recover, an inflection point (so relevant now) 👉to a new BETTER normal
@RheumNow https://t.co/UMKIC1tNos
sheila RHEUMarampa ( View Tweet)
#ACR21 #YearinReview
Avacopan: The game changer for ANCA #vasculitis?🧐
🔅Remission at wk 26: Avacopan non-inferior to Pred (72.3% vs. 70.1%, p<0.001)
🔅Sustained remission at wk 56: Avacopan non-inferior to Pred (65.7% vs. 54.9%, p<0.001)
@RheumNow
https://t.co/CpPYVvRoMR https://t.co/QnsZIUQ0uu
Links:
sheila RHEUMarampa ( View Tweet)
The AURORA 1 trial provided positive results for #lupus nephritis 👉rapid control of proteinuria w/o major side effects.
@RheumNow #ACR21 #YearinReview https://t.co/BWWZJtMPK0
sheila RHEUMarampa ( View Tweet)
To cut back or continue? 🤔
The ARCTIC REWIND trial showed that RA pts in remission given half dose csDMARDs had ⬆ flares in 12 mos vs. stable dose csDMARD grp.
@RheumNow #ACR21 #YearinReview https://t.co/MXyD0epVcn
sheila RHEUMarampa ( View Tweet)
Excited for the first full day of #ACR21, reporting for @RheumNow!
Esp looking forward to:
⭐Posters: #Epidemiology, #PublicHealth, #COVID19, #SpA, #RheumatoidArthritis, #PatientOutcomes
⭐Plenary session
⭐Scientific sessions covering #axSpA, #PsA and more
Mrinalini Dey DrMiniDey ( View Tweet)
Some great #SpA posters on #WorkParticipation
#ACR21
Abs#0358
•~700 pts
•379 (64.2%) took sick leave in last 12m
•#Absenteeism in 23.7% & #presenteeism in 84.1%
•Huge impact on work participation in SpA despite incr no. of therapeutic agents
@RheumNow
https://t.co/pwz4s8D1FU https://t.co/wpbjeXNpgm
Mrinalini Dey DrMiniDey ( View Tweet)